Spread the love


A yet2 client is seeking in-licensing opportunities for late-stage clinical or approved novel therapeutics to treat rare neurological disorders, including but not limited to neuromuscular, neuroinflammatory, and neuropathy.


Therapeutics will:

  • Be already approved or in late-stage clinical (have a minimum of Phase II data)
  • Be based on small molecules, biological or oligonucleotide modalities (e.g., siRNA, miRNA)
    • Cell therapy, CRISPR, or similar gene editing approaches are not of interest.
  • Be designated/approved/marketed for rare or orphan diseases


Desired Outcome of the Solution

In-licensing partnership

Related Tech Needs


Photo by Towfiqu barbhuiya on Unsplash

Spread the love